Results from a late-stage study show that Pfizer's (PFE) RSV vaccine generated strong neutralizing responses in immunocompromised adults after receiving a single dose.

Pfizer posted positive growth during the second quarter, a heartening sign for shareholders. Strong demand for several products beyond its COVID-19 portfolio supports a positive outlook.

Eli Lilly is a giant in the world of weight loss drugs, generating billions of dollars in revenue. Rival big pharma player Pfizer aims to get in on this major market.

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a b...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...

Pfizer beat pharma records when its annual revenue soared past $100 billion in 2022, thanks to its coronavirus vaccine and treatment. As demand for these products slowed, revenue dropped -- so the ...

Drugmaker Pfizer reported quarterly earnings above expectations on Tuesday as it raised full year guidance on the back of strong sales of non-Covid products.

Pfizer Inc's (NYSE:PFE, ETR:PFE) stock is up ahead of the bell after the company raised its annual profit forecast following stronger-than-expected sales of its Covid vaccine and antiviral treatmen...

Pfizer Inc. PFE is scheduled to release its financial results for the second quarter, before the opening bell on Tuesday.

Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz. Technical analysis tools show bullish trends: trading above 30-week EMA, increasing momentum, and improving rela...

Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that front isn't exactly a sizzler.

Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.

Medical Properties Trust pays investors a high yield, but the stock carries significant risk. Pfizer's more modest yield of 6% is still well above average, and the dividend has been increasing in r...

Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday.